Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications
Nicolas Wein, Diane M. Dunn, Megan A. Waldrop, et al.
Human Gene Therapy (2021)
Closed Access | Times Cited: 15

Showing 15 citing articles:

Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy
Harry Wilton-Clark, Toshifumi Yokota
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 778-778
Open Access | Times Cited: 34
Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
Cédric Happi Mbakam, Gabriel Lamothe, Jacques P. Tremblay
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 31
Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot
Harry Wilton-Clark, Toshifumi Yokota
Genes (2022) Vol. 13, Iss. 2, pp. 257-257
Open Access | Times Cited: 24
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
Nicolas Wein, Tatyana A. Vetter, Adeline Vulin, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 279-293
Open Access | Times Cited: 23
Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing
David N. Fiflis, N.A. Rey, Harshitha Venugopal-Lavanya, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies
Sina Fatehi, Ryan M. Marks, M. Rok, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 9-10, pp. 388-403
Closed Access | Times Cited: 13
The 2022 On-site Padua Days on Muscle and Mobility Medicine hosts the University of Florida Institute of Myology and the Wellstone Center, March 30 - April 3, 2022 at the University of Padua and Thermae of Euganean Hills, Padua, Italy: The collection of abstracts
H. Lee Sweeney, Stefano Masiero, Ugo Carraro
European Journal of Translational Myology (2022) Vol. 32, Iss. 1
Open Access | Times Cited: 16
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies – Developing Potential Treatments for the Entire Spectrum of Disease
Craig M. McDonald, Eric Camino, Rafael Escandon, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 499-523
Open Access | Times Cited: 3
Recent Trends in Antisense Therapies for Duchenne muscular dystrophy
Harry Wilton-Clark, Toshifumi Yokota
(2023)
Open Access | Times Cited: 8
RNA-Based Therapeutic Technology
Ryuichi Mashima, Shuji Takada, Yoshitaka Miyamoto
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15230-15230
Open Access | Times Cited: 5
Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
Liubov V. Gushchina, A. Bradley, Tatyana A. Vetter, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101144-101144
Open Access | Times Cited: 5
Strategies for Bottlenecks of rAAV-Mediated Expression in Skeletal and Cardiac Muscle of Duchenne Muscular Dystrophy
Na Li, Yafeng Song
Genes (2022) Vol. 13, Iss. 11, pp. 2021-2021
Open Access | Times Cited: 4
Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications
Thomas C. Roberts
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101160-101160
Open Access | Times Cited: 1
Design and evaluation of antisense sequence length for modified mouse U7 small nuclear RNA to induce efficient pre-messenger RNA splicing modulation in vitro
Takenori Shimo, Otoya Ueda, Satoshi Yamamoto
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0305012-e0305012
Open Access
A Cautiously Optimistic Outlook of a Designer Therapy for 1% of Duchenne Muscular Dystrophy Patients
Dongsheng Duan
Human Gene Therapy (2021) Vol. 32, Iss. 17-18, pp. 872-874
Open Access
Page 1

Scroll to top